NCT05109078View on ClinicalTrials.gov

ADME Study of [14C]- Rongliflozin in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 9, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Healthy Adult Male Volunteers
Interventions
DRUG

[14C]- Rongliflozin

Patients will receive single dose of orally \[14C\]- Rongliflozin on Day 1

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT05109078 - ADME Study of [14C]- Rongliflozin in Healthy Male Subjects | Biotech Hunter | Biotech Hunter